- Oops!Something went wrong.Please try again later.
Pasithea Therapeutics Corp's (NASDAQ: KTTA) wholly-owned subsidiary, Pasithea Clinics, has administered intravenous (IV) ketamine therapy to its first patients with treatment-resistant depression.
Pasithea Clinics commenced IV ketamine infusion therapy in Knightsbridge, London.
In sub-anesthetic doses, ketamine has shown efficacy and a rapid and sustained effect in some psychiatric disorders, such as treatment-resistant depression and post-traumatic stress disorder.
Ketamine is an FDA-approved anesthetic and was introduced over 50 years ago. It has recently been repurposed in significantly lower doses to treat psychiatric disorders.
Pasithea has clinical partnerships to administer its IV ketamine treatment. In the U.K., Pasithea has partnered with ZEN Healthcare – a network of health clinics in London.
In the U.S., it has partnered with The IV Doc Inc to provide in-home IV ketamine infusions.
Price Action: KTTA shares closed 1.50% higher at $2.71 on Tuesday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.